ClinVar Miner

Submissions for variant NM_000038.6(APC):c.4395T>A (p.Ser1465Arg)

gnomAD frequency: 0.00004  dbSNP: rs779898882
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 12
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV000198718 SCV000254015 likely benign Familial adenomatous polyposis 1 2025-01-23 criteria provided, single submitter clinical testing
GeneDx RCV000766728 SCV000293401 uncertain significance not provided 2025-01-31 criteria provided, single submitter clinical testing Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis indicates that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 27194209, 21859464, 26336887, 18369740, 30306255, 25742471, 26862949, 18199528)
Color Diagnostics, LLC DBA Color Health RCV000446409 SCV000537583 uncertain significance Hereditary cancer-predisposing syndrome 2023-04-17 criteria provided, single submitter clinical testing This missense variant replaces serine with arginine at codon 1465 of the APC protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with APC-related disorders in the literature. This variant has been identified in 4/251176 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.
Ambry Genetics RCV000446409 SCV000579788 likely benign Hereditary cancer-predisposing syndrome 2020-09-28 criteria provided, single submitter clinical testing This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000236990 SCV000600100 uncertain significance not specified 2017-05-08 criteria provided, single submitter clinical testing
Counsyl RCV000198718 SCV000784952 uncertain significance Familial adenomatous polyposis 1 2017-02-16 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000236990 SCV001478762 uncertain significance not specified 2021-01-30 criteria provided, single submitter clinical testing Variant summary: APC c.4395T>A (p.Ser1465Arg) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 1.6e-05 in 251176 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.4395T>A has been reported in the literature in individuals affected with breast cancer but not in the setting of familial adenomatous polyposis (example, Gurda_2017, Bonache_2018). These report(s) do not provide unequivocal conclusions about association of the variant with Familial Adenomatous Polyposis. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Six clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Multiple laboratories reported the variant with conflicting assessments (likely benign, n=2; VUS, n=4), some citing overlapping evidence utilized in the context of this evaluation. Based on the evidence outlined above, the variant was classified as uncertain significance.
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000766728 SCV002050070 uncertain significance not provided 2020-11-14 criteria provided, single submitter clinical testing The APC c.4395T>A; p.Ser1465Arg variant (rs779898882) has been published in the germline of at least one individual undergoing multi-gene cancer testing (Wong 2015). The variant is reported in the ClinVar database (Variation ID: 216164) and is found in the European (non-Finnish) population with an allele frequency of 0.004% (4/113,506 alleles) in the Genome Aggregation Database. The serine at codon 1465 is moderately conserved, but computational analyses are uncertain whether this variant is neutral or deleterious (REVEL: 0.175). However, the vast majority of pathogenic APC variants are truncating nonsense or frameshift variants (see InSiGHt, Kerr 2013). Due to limited information, the clinical significance of the p.Ser1465Arg variant is uncertain at this time. References: Link to InSiGHt: https://www.insight-group.org/syndromes/adenomatous-polyposis/. Kerr SE et al. APC germline mutations in individuals being evaluated for familial adenomatous polyposis: a review of the Mayo Clinic experience with 1591 consecutive tests. J Mol Diagn. 2013 Jan;15(1):31-43. Wong SQ et al. Assessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients. Br J Cancer. 2015 Apr 14;112(8):1411-20.
Genetic Services Laboratory, University of Chicago RCV000236990 SCV002071948 uncertain significance not specified 2021-10-19 criteria provided, single submitter clinical testing DNA sequence analysis of the APC gene demonstrated a sequence change, c.4395T>A, in exon 16 that results in an amino acid change, p.Ser1465Arg. This sequence change has been described in the gnomAD database with a frequency of 0.004% in the non-Finnish European subpopulation (dbSNP rs779898882). The p.Ser1465Arg change affects a moderately conserved amino acid residue located in a domain of the APC protein that is not known to be functional. The p.Ser1465Arg substitution appears to be benign using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). This sequence change has been previously reported in an individual with clear cell renal cell carcinoma (PMID: 25742471). Due to insufficient evidences and the lack of functional studies, the clinical significance of the p.Ser1465Arg change remains unknown at this time.
Sema4, Sema4 RCV000446409 SCV002532060 uncertain significance Hereditary cancer-predisposing syndrome 2022-02-02 criteria provided, single submitter curation
Myriad Genetics, Inc. RCV000198718 SCV004018966 uncertain significance Familial adenomatous polyposis 1 2023-02-15 criteria provided, single submitter clinical testing This variant is classified as a variant of uncertain significance as there is insufficient evidence to determine its impact on protein function and/or cancer risk.
All of Us Research Program, National Institutes of Health RCV003996975 SCV004837927 uncertain significance Classic or attenuated familial adenomatous polyposis 2024-08-30 criteria provided, single submitter clinical testing This missense variant replaces serine with arginine at codon 1465 of the APC protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). Splice site prediction tools suggest that this variant may not impact RNA splicing. To our knowledge, functional studies have not been performed for this variant. This variant has been reported in an individual affected with an unspecified cancer (PMID: 25742471). This variant has been identified in 4/251176 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.